Privacy preference

MEDtalks would like to keep you informed about the content that is most relevant to you. Click here for more information.


Quarterly Focus on Hematology | CLL

Treating patients with chronic lymphocytic leukemia in an optimal fashion seems to become more complex every day. After all, our knowledge of the underlying biological complexity keeps on growing, creating new subgroups of patiets, and on top of that new potential drug combinations are constantly being developed and presented.

In this program, a very international discussion panel will guide you through 2 highly relevant publications, helping you better understan the latest developments in the field of CLL.

Guests

  • Prof. Arnon Kater, MD, PhD
    • Hematologist, Amsterdam UMC (AMC), The Netherlands
  • Prof. Stephan Stilgenbauer, MD
    • Hematologist, Saarland University, Homburg & Ulm University, Ulm, Germany
  • Gert Jan Timmers, MD, PhD
    • Hematologist, Amstelland Ziekenhuis, Amstelveen, The Netherlands
  • Prof. Paolo Ghia, MD, PhD
    • Internist, Università Vita-Salute San Raffaele, Milan, Italy
  • Kostas Stamatopoulos, MD, PhD
    • CERTH, Thessaloniki, Greece  

Publications to be discussed

  1. Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study - Kater et al., JCO, december 2018

  2. Cytogenetic Complexity in Chronic Lymphocytic Leukemia: Definitions, Assiciations and Clinical Impact - Baliakas et al, Blood, January 2019

About our "Quarterly Focus" format

Publications in peer-reviewed journals are a major source for keeping up with the latest developments in your field. However, you may not always have sufficient time to study (difficult) publications thoroughly and to determine the impact on your clinical practice. To support you, MEDtalks Hematology has developed a new program format: the Quarterly Focus. This innovative program brings an expert panel and authors of relevant, selected publications together to explain and discuss the new data.  

Related items

Congress news 30/09/2019

iwCLL 2019 Highlight: frontline treatment

What are the recommendations for frontline treatment of CLL?  Valentin Goede, MD, hematologist at St. Marien-Hospital in Cologne (Germany), discusses frontline treatment in young and older CLL patients. Prof. Paolo Ghia, MD, medical oncologist at Vita-Salute San Raffaele University in Milan (Italy), catches up on the use of biomarkers to choose the right treatment. Prof. Dominique Bron, MD, hematologist at Jules Bordet Institute in Brussels (Belgium), gives her vision on how to make a choice in frontline CLL treatment. 

Congress news 30/09/2019

iwCLL 2019 Highlight: future treatment of CLL

Prof. Anna Schuh, MD, hematologist at the University of Oxford (UK), talks about future management of CLL.  David Maloney, MD, PhD, hematologist at the Fred Hutchinson Cancer Research Center in Seattle (USA), talks about CAR-T cell therapy in CLL. 

Congress news 26/09/2019

iwCLL 2019 Highlight: relapse treatment

What are the recommendations for treatment of relapsed CLL patients?  Prof. John Seymour, MD, hematologist at the Peter MacCallum Cancer Centre in Melbourne, Australia, talks about BCL2-inhibitors and MRD in relapsed/refractory disease.  Talha Munir, MD, PhD, hematologist at St James’s Hospital in Leeds (UK), explains about the role of MRD in determining the duration of therapy.

Congress news 25/09/2019

iwCLL 2019 Highlight: diagnostic tests

What is the latest news in the field of diagnostic testing at CLL? Prof. Richard Rosenquist, MD, hematologist at the Karolinska University Hospital in Stockholm (Sweden), explains the molecular characterization of CLL.  Andy Rawstron, MD, PhD, clinical researcher at the St. James Institute of Oncology in Leeds (UK), talks about diagnostic tests for CLL, including MRD as an end point. 

Congress news 10/09/2019

Highlights from the iwCLL 2019 in Edinburgh

The 18th International Workshop on CLL (iwCLL) will take place in Auld Reekie - as Edinburgh used to be called by the Scots - from 20 to 23 September. Are you unable to attend this congress? No worries, MEDtalks will travel to this historic city to bring you the most important news about chronic lymphocytic leukemia (CLL). What news is told about diagnostic tests on CLL? And what are the recommendations for the treatment of patients in the frontline and later lines? Renowned hematologists/researchers will talk about this and more in a series of interviews that can be viewed on our website from the beginning of October. Interviews Diagnostic tests Prof. Richard Rosenquist, MD - hematologist, Karolinska University Hospital, Stockholm, Sweden.  Andy Rawstron, MD, PhD - clinical researcher, St. James Institute of Oncology, Leeds, UK.  CLL immunogenetics and B-cell receptor stereotypes Dr. Kostas Stamatopoulos - physician-scientist, Institute of Applied Forest Sciences CERTH, Thessaloniki, Greece.   The role of NOTCH1 and Richter’s transformation Silvia Deaglio, MD, PhD - oncologist, University of Turin, Italy.  Frontline treatment What are the recommendations for frontline treatment of CLL?  Valentin Goede, MD, hematologist at St. Marien-Hospital in Cologne (Germany), discusses frontline treatment in young and older CLL patients. Prof. Paolo Ghia, MD, medical oncologist at Vita-Salute San Raffaele University in Milan (Italy), catches up on the use of biomarkers to choose the right treatment. Prof. Dominique Bron, MD, hematologist at Jules Bordet Institute in Brussels (Belgium), gives her vision on how to make a choice in frontline CLL treatment.  Relapse treatment Prof. John Seymour, MD - hematologist, Peter MacCallum Cancer Centre, Melbourne, Australia.  Talha Munir, MD, PhD - hematologist, St James’s Hospital, Leeds, UK.   Future treatment of CLL Prof. Anna Schuh, MD, hematologist at the University of Oxford (UK), talks about future management of CLL.  David Maloney, MD, PhD, hematologist at the Fred Hutchinson Cancer Research Center in Seattle (USA), talks about CAR-t cell therapy in CLL.  By registering you gain access to the interviews.

Congress news 08/12/2014

ASH 2014 Highlight 3 - Leukemia

Highlight on leukemia: Prof. Dr. med. Uwe Platzbecker tells if ATRA+arsenicumtrioxide should become the new standard care for non-high risk APML by illustrating the Italian-German APL0406 trial. Ian Flinn MD PhD provides an overview on novel therapies for CLL. Prof. Dr. Michele Baccarani discusses whether imatinib remains the standard therapy for CML by elaborating on the DASISION, SPIRIT-2 and EPIC trails. Prof. Dr. Rien van Oers concludes with the PROLONG trial which investigates ofatumumab maintenance therapy in R/R CLL.

Congress news 12/06/2014

EHA 2014 - News Report 1

EHA 2014 – News Report 1 on: CLL by Prof. Stephan Stilgenbauer, the José Carreras Lecture ‘Genetics to guide management of patients with AML by Prof. Hartmut Döhner, the pathophysiology of auto-immune hemolytic anemia by Prof. Hannah Tamary and Stem Cell Transplantation: focus on chronic GvHD by Prof William Arcese.